-
CHI3L1-IN-5: Astrocyte Assay Workflows
2026-09-12
CHI3L1-IN-5, also called Compound Z17, supports a dual readout strategy: suppressing CHI3L1-driven inflammation while testing astrocyte Aβ clearance and lysosomal recovery. This workflow-focused guide covers dose design, CNS-relevant interpretation, assay controls, and troubleshooting for Alzheimer’s disease and neuroinflammation research.
-
Merbromin Inhibits SARS-CoV-2 3CLpro
2026-09-11
A high-throughput enzyme screen of approximately 6,000 compounds identified Merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 3CLpro/Mpro protease. The study combines kinetic analysis, binding measurements, and molecular docking to show how this fluorescent antibacterial compound can serve as a starting point for antiviral screening and protease-inhibitor design.
-
Flumequine as a DNA Topoisomerase II Inhibitor
2026-09-11
Flumequine is a synthetic chemotherapeutic antibiotic described as a DNA topoisomerase II inhibitor with a supplier-reported IC50 of approximately 15 μM. Its defined solubility, storage, purity, and viability-assay considerations support controlled DNA replication research while limiting interpretation to the reported assay context.
-
MLN4924 HCl Salt in NAE Research
2026-09-10
MLN4924 HCl salt enables controlled interrogation of NAE-dependent protein turnover, cullin-RING ligase activity, and cell-death signaling. Its strongest use-case is a staged workflow that connects biochemical pathway inhibition with cancer biology research and virus-induced inflammation assays.
-
RNA Pol II Degradation and Regulated Cell Death
2026-09-10
Harper et al. show that RNA Pol II inhibition can trigger apoptosis through active sensing of RNA Pol IIA depletion rather than through transcriptional collapse alone. Their PDAR model separates polymerase abundance from transcriptional activity and provides a framework for interpreting drug-induced cell death in mechanistic cancer biology research.
-
Cefotaxime: A Transferability Lens for AMR Assays
2026-09-09
Cefotaxime is a third-generation cephalosporin antibiotic that can do more than establish susceptibility endpoints. This article shows how to use it as a controlled phenotypic probe alongside plasmid, mobility, and strain-typing data in antimicrobial resistance research.
-
PP2A, Autophagy, and Candida Biofilm Resistance
2026-09-09
The reference study identifies a PP2A–Atg13–Atg1 regulatory axis that connects autophagy with Candida albicans biofilm formation and antifungal drug resistance. By combining PPH21 deletion, rapamycin-induced autophagy, cellular assays, and an oral infection model, it suggests that disrupting PP2A-dependent autophagy may improve antifungal treatment responses.
-
Ceftolozane Sulfate: From Target to Translation
2026-09-08
Ceftolozane sulfate connects PBP3-directed bactericidal activity with reproducible susceptibility and PK/PD research. This guide presents an assay-to-model framework that clarifies ceftolozane MIC values, experimental controls, and translational limitations.
-
SB-505124 hydrochloride for TGF-β Assays
2026-09-08
Use SB-505124 hydrochloride to separate TGF-β/activin-driven Smad signaling from downstream fibrosis, differentiation, and cell-mechanics phenotypes. This workflow also shows how to extend pathway inhibition into mechanobiology assays without confusing ALK signaling effects with direct potassium-channel modulation.
-
5-(N,N-dimethyl)-Amiloride: NHE Inhibition
2026-09-07
5-(N,N-dimethyl)-Amiloride hydrochloride is a research inhibitor of NHE1, NHE2, and NHE3 that helps dissect intracellular pH regulation and sodium transport. Its strongest documented utility is mechanistic ion-transport research, including cardiac ischemia-reperfusion models, rather than clinical treatment.
-
Heterologous Regulators Improve A40926 Production
2026-09-05
The reference study shows that StrR-like regulators from phylogenetically distant lipodepsipeptide pathways can influence glycopeptide antibiotic biosynthesis in heterologous hosts. Chers28 enhanced teicoplanin and A40926 production, whereas ramo5 did not, revealing both the potential and selectivity of regulator-based activation strategies.
-
Sphingosine-1-phosphate Assay Workflows
2026-09-05
Build receptor-aware S1P assays that separate endothelial signaling from neuronal stress and apoptosis. This workflow combines fresh-solution handling, kinetic pathway sampling, and orthogonal validation to make S1PR1- and S1PR3-linked outcomes easier to interpret.
-
Quercetin Inhibits Ferroptosis in Wilson Disease
2026-09-04
A 2026 Phytomedicine study identifies ferroptosis as a mechanistic contributor to copper-associated liver injury in Wilson disease and shows that Quercetin can suppress this process. The work links Quercetin activity to direct interaction with ACSL4 and inhibition of the ACSL4/LPCAT3/ALOX15 lipid-peroxidation axis, while also restoring iron, redox, lipid, and mitochondrial homeostasis.
-
Phebestin: Nanomolar Antiplasmodial Activity
2026-09-04
The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a nanomolar inhibitor of both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Its stage-spanning activity, persistent effects after washout, low fibroblast cytotoxicity, and efficacy in mouse malaria models support aminopeptidases as a useful but still investigational antimalarial target.
-
Reserpine (N1867): Practical Lab Guide
2026-09-03
Reserpine (N1867) is a characterized research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide addresses identity checks, DMSO-based preparation, storage, and assay QC; the compound is not intended for diagnostic, therapeutic, or medical use.